From the Journals

Shunt diameter predicts liver function after obliteration procedure


 

FROM JGH OPEN

Study supports potential benefits of BRTO

“While the association between SPSS and complications of portal hypertension such as variceal bleeding and hepatic encephalopathy have been known, data are lacking in regard to characteristics of SPSS that are most dysfunctional, and whether certain patients may benefit from BRTO to occlude these shunts,” Khashayar Farsad, MD, of Oregon Health & Science University, Portland, said in an interview.

Khashayar Farsad, MD, of Oregon Health and Science University, Portland

Dr. Khashayar Farsad

“The results are in many ways expected based on anticipated impact of larger versus smaller SPSS in overall liver function,” Dr. Farsad noted. “The study, however, does show a nice correlation between several factors involved in liver function and their changes depending on shunt diameter, correlated with changes in the relative venous pressure gradient across the liver,” he said. “Furthermore, the finding that changes were most evident in those with relatively preserved liver function [Child-Turcotte-Pugh grades A and B] suggests less of a relationship between SPSS and liver function in those with more decompensated liver disease,” he added.

“The impact of the study is significantly limited by its retrospective design, small numbers with potential patient heterogeneity, and lack of a control cohort,” said Dr. Farsad. However, “The major take-home message for clinicians is a potential signal that the size of the SPSS at baseline may predict the impact of the SPSS on liver function, and therefore, the potential benefit of a procedure such as BRTO to positively influence this,” he said. “Additional research with larger cohorts and a prospective study design would be warranted, however, before this information would be meaningful in daily clinical decision making,” he emphasized.

The study was supported by the Research Program on Hepatitis of the Japanese Agency for Medical Research and Development. The researchers had no financial conflicts to disclose. Dr. Farsad disclosed research support from W.L. Gore & Associates, Guerbet LLC, Boston Scientific, and Exelixis; serving as a consultant for NeuWave Medical, Cook Medical, Guerbet LLC, and Eisai, and holding equity in Auxetics Inc.

Pages

Recommended Reading

AGA Clinical Practice Update: Commentary on noninvasive CRC screening
MDedge Internal Medicine
Topical steroid shows promise for EOE
MDedge Internal Medicine
RFA has long-lasting protective effects in esophageal cancer
MDedge Internal Medicine
Can colorectal ESD succeed in outpatient settings?
MDedge Internal Medicine
Can green tea extract protect against colorectal adenomas?
MDedge Internal Medicine
Bowel ultrasound may overtake colonoscopy in Crohn’s
MDedge Internal Medicine
Registry data support lowering CRC screening age to 45
MDedge Internal Medicine
AI-assisted colonoscopy cuts adenoma miss rate in half
MDedge Internal Medicine
FDA approves upadacitinib for ulcerative colitis
MDedge Internal Medicine
Excess weight over lifetime hikes risk for colorectal cancer
MDedge Internal Medicine